Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Postviral Research Stockholm AB
AB
In liquidation
Org 5594246984
Stockholm
Other research and experimental development on natural sciences and engineering
· NACE 7219
Est. 2023
0 employees
Watchlist
Share
Sweden
/
Companies
/
Other research and experimental development on natural sciences and engineering
/
Postviral Research Stockholm AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2023
EBITDA
SEK millions
0M
-0M
-1M
-1M
-1M
-1M
2023
Income statement
SEK thousands
Item
2023
Revenue
0
Staff expenses
—
EBITDA
−898
Depreciation & amort.
−0
EBIT
−898
Net financials
—
Profit before tax
0
Tax
−0
Net profit
0
Balance sheet
SEK thousands
Item
2023
Total assets
307
Equity
125
Long-term debt
0
Short-term debt
182
Total debt
182
Financial ratios
5-year trend
EBITDA margin
-89800000.0%
This company
15.8%
Market median
-568354530% vs market
2023
2023
Equity ratio
40.7%
This company
38.2%
Market median
+7% vs market
2023
2023
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
2023
2023
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
2023
2023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2023
2023
Debt / equity
1.46×
This company
0.62×
Market median
-135% vs market
2023
2023
Annual reports & filings
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-03-01 – 2023-12-31
View
PDF
More on Postviral Research Stockholm AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
